|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sugai T, Habano W, Jiao YF, Tsukahara M,
Takeda Y, Otsuka K and Nakamura S: Analysis of molecular
alterations in left- and right-sided colorectal carcinomas reveals
distinct pathways of carcinogenesis: Proposal for new molecular
profile of colorectal carcinomas. J Mol Diagn. 8:193–201. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee GH, Malietzis G, Askari A, Bernardo D,
Al-Hassi HO and Clark SK: Is right-sided colon cancer different to
left-sided colorectal cancer? A systematic review. Eur J Surg
Oncol. 41:300–308. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Takahashi Y, Sugai T, Habano W, Ishida K,
Eizuka M, Otsuka K, Sasaki A, Takayuki M, Morikawa T, Unno M and
Suzuki H: Molecular differences in the microsatellite stable
phenotype between left-sided and right-sided colorectal cancer. Int
J Cancer. 139:2493–2501. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Minoo P, Zlobec I, Peterson M, Terracciano
L and Lugli A: Characterization of rectal, proximal and distal
colon cancers based on clinicopathological, molecular and protein
profiles. Int J Oncol. 37:707–718. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gao XH, Yu GY, Gong HF, Liu LJ, Xu Y, Hao
LQ, Liu P, Liu ZH, Bai CG and Zhang W: Differences of protein
expression profiles, KRAS and BRAF mutation, and prognosis in
right-sided colon, left-sided colon and rectal cancer. Sci Rep.
7:78822017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Salem ME, Yin J, Weinberg BA, Renfro LA,
Pederson LD, Maughan TS, Adams RA, Van Cutsem E, Falcone A, Tebbutt
NC, et al: Clinicopathological differences and survival outcomes
with first-line therapy in patients with left-sided colon cancer
and rectal cancer: Pooled analysis of 2,879 patients from AGITG
(MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD
database. Eur J Cancer. 103:205–213. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bogaert J and Prenen H: Molecular genetics
of colorectal cancer. Ann Gastroenterol. 27:9–14. 2014.PubMed/NCBI
|
|
9
|
Worthley DL and Leggett BA: Colorectal
cancer: Molecular features and clinical opportunities. Clin Biochem
Rev. 31:31–38. 2010.PubMed/NCBI
|
|
10
|
Tie J, Gibbs P, Lipton L, Christie M,
Jorissen RN, Burgess AW, Croxford M, Jones I, Langland R, Kosmider
S, et al: Optimizing targeted therapeutic development: Analysis of
a colorectal cancer patient population with the BRAF(V600E)
mutation. Int J Cancer. 128:2075–2084. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Salem ME, Weinberg BA, Xiu J, El-Deiry WS,
Hwang JJ, Gatalica Z, Philip PA, Shields AF, Lenz HJ and Marshall
JL: Comparative molecular analyses of left-sided colon, right-sided
colon, and rectal cancers. Oncotarget. 8:86356–86368. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ahadova A, von Knebel Doeberitz M, Bläker
H and Kloor M: CTNNB1-mutant colorectal carcinomas with immediate
invasive growth: A model of interval cancers in Lynch syndrome. Fam
Cancer. 15:579–586. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cheng DT, Mitchell TN, Zehir A, Shah RH,
Benayed R, Syed A, Chandramohan R, Liu ZY, Won HH, Scott SN, et al:
Memorial Sloan Kettering-integrated mutation profiling of
actionable cancer targets (MSK-IMPACT): A hybridization
capture-based next-generation sequencing clinical assay for solid
tumor molecular oncology. J Mol Diagn. 17:251–264. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zehir A, Benayed R, Shah RH, Syed A,
Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, et
al: Mutational landscape of metastatic cancer revealed from
prospective clinical sequencing of 10,000 patients. Nat Med.
23:703–713. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Phipps AI, Limburg PJ, Baron JA,
Burnett-Hartman AN, Weisenberger DJ, Laird PW, Sinicrope FA, Rosty
C, Buchanan DD, Potter JD and Newcomb PA: Association between
molecular subtypes of colorectal cancer and patient survival.
Gastroenterology. 148:77–87.e2. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Govindan R, Ding L, Griffith M,
Subramanian J, Dees ND, Kanchi KL, Maher CA, Fulton R, Fulton L,
Wallis J, et al: Genomic landscape of non-small cell lung cancer in
smokers and never-smokers. Cell. 150:1121–1134. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Slattery ML, Curtin K, Anderson K, Ma KN,
Ballard L, Edwards S, Schaffer D, Potter J, Leppert M and Samowitz
WS: Associations between cigarette smoking, lifestyle factors, and
microsatellite instability in colon tumors. J Natl Cancer Inst.
92:1831–1836. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chia VM, Newcomb PA, Bigler J, Morimoto
LM, Thibodeau SN and Potter JD: Risk of microsatellite-unstable
colorectal cancer is associated jointly with smoking and
nonsteroidal anti-inflammatory drug use. Cancer Res. 66:6877–6883.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wood LD, Parsons DW, Jones S, Lin J,
Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, et al: The
genomic landscapes of human breast and colorectal cancers. Science.
318:1108–1113. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fodde R: The APC gene in colorectal
cancer. Eur J Cancer. 38:867–871. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Iacopetta B: TP53 mutation in colorectal
cancer. Hum Mutat. 21:271–276. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ficari F, Cama A, Valanzano R, Curia MC,
Palmirotta R, Aceto G, Esposito DL, Crognale S, Lombardi A,
Messerini L, et al: APC gene mutations and colorectal adenomatosis
in familial adenomatous polyposis. Br J Cancer. 82:348–353. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu J and Attisano L: Mutations in the
tumor suppressors Smad2 and Smad4 inactivate transforming growth
factor beta signaling by targeting Smads to the
ubiquitin-proteasome pathway. Proc Natl Acad Sci USA. 97:4820–4825.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li X, Liu B, Xiao J, Yuan Y, Ma J and
Zhang Y: Roles of VEGF-C and Smad4 in the lymphangiogenesis,
lymphatic metastasis, and prognosis in colon cancer. J Gastrointest
Surg. 15:2001–2010. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang B, Zhang B, Chen X, Bae S, Singh K,
Washington MK and Datta PK: Loss of Smad4 in colorectal cancer
induces resistance to 5-fluorouracil through activating Akt
pathway. Br J Cancer. 110:946–957. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mehrvarz Sarshekeh A, Advani S, Overman
MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E,
Manuel S, et al: Association of SMAD4 mutation with patient
demographics, tumor characteristics, and clinical outcomes in
colorectal cancer. PLoS One. 12:e01733452017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Therkildsen C, Bergmann TK,
Henrichsen-Schnack T, Ladelund S and Nilbert M: The predictive
value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment
in metastatic colorectal cancer: A systematic review and
meta-analysis. Acta Oncol. 53:852–864. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mao C, Yang ZY, Hu XF, Chen Q and Tang JL:
PIK3CA exon 20 mutations as a potential biomarker for resistance to
anti-EGFR monoclonal antibodies in KRAS wild-type metastatic
colorectal cancer: A systematic review and meta-analysis. Ann
Oncol. 23:1518–1525. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sartore-Bianchi A, Martini M, Molinari F,
Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P,
De Dosso S, Mazzucchelli L, et al: PIK3CA mutations in colorectal
cancer are associated with clinical resistance to EGFR-targeted
monoclonal antibodies. Cancer Res. 69:1851–1857. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
De Roock W, Claes B, Bernasconi D, De
Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V,
Papamichael D, Laurent-Puig P, et al: Effects of KRAS, BRAF, NRAS,
and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy
in chemotherapy-refractory metastatic colorectal cancer: A
retrospective consortium analysis. Lancet Oncol. 11:753–762. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Italiano A, Hostein I, Soubeyran I, Fabas
T, Benchimol D, Evrard S, Gugenheim J, Becouarn Y, Brunet R, Fonck
M, et al: KRAS and BRAF mutational status in primary colorectal
tumors and related metastatic sites: Biological and clinical
implications. Ann Surg Oncol. 17:1429–1434. 2010. View Article : Google Scholar : PubMed/NCBI
|
